TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has provided an announcement.
Lumos Diagnostics has achieved full U.S. Medicare reimbursement recognition for its FebriDx® test, securing approval from all seven Medicare Administrative Contractors (MACs), including the final approval from National Government Services. This development ensures FebriDx is positioned for broad adoption across the U.S. healthcare system, facilitating access through Medicare Advantage, Medicaid, and private payors. The company will now focus on assisting MACs in developing written policies to streamline reimbursement claims, enhancing clarity and predictability for stakeholders.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.
Average Trading Volume: 5,211,203
Technical Sentiment Signal: Buy
Current Market Cap: A$133.8M
For an in-depth examination of LDX stock, go to TipRanks’ Overview page.